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Background: Opiates are the main drugs of abuse, and Methadone Maintenance Treatment (MMT) is the most widely
administered drug addiction treatment program in Iran. Our study aimed to investigate patterns of pre-treatment drug
abuse, addiction treatment history and characteristics of patients in MMT in Tehran.
Methods: We applied a stratified cluster random sampling technique and conducted a cross-sectional survey utilizing a
standard patient characteristic and addiction history form with patients (n= 810) in MMT. The Chi-square test and t-test
served for statistical analyses.
Results: A clear majority of the participants were men (96%), more than 60% of whom were between 25 and 44 years
of age, educated (89% had more than elementary education), and employed (>70%). The most commonly reported
main drugs of abuse prior to MMT entry were opium (69%) and crystalline heroin (24%). The patients’ lifetime drug
experience included opium (92%), crystalline heroin (28%), cannabis (16%), amphetamines (15%), and other drugs
(33%). Crystalline heroin abusers were younger than opium users, had begun abusing drugs earlier, and reported a
shorter history of opiate addiction.
Conclusion: Opium and crystalline heroin were the main drugs of abuse. A high rate of addiction using more
dangerous opiate drugs such as crystalline heroin calls for more preventive efforts, especially among young men.
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Drug abuse is among the most challenging and costly
health problems that lead to a broad range of physical,
mental, and psychiatric consequences, and poses a huge
public health problem worldwide [1]. Opioids are the
third most widely used group of drugs after cannabis
and amphetamine-type stimulants. Among opioids, opi-
ates are the most problematic and harmful substances
consumed by 12 to 21 million people worldwide. The
highest consumption rate of opiates is in countries in
Southwest Asia [2].
Iran, located along the opium trade route, has the high-
est rate of opiate drug use worldwide [3]. Based on the
most recent national survey of drug abuse in Iran, the* Correspondence: jorma.virtanen@oulu.fi
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distribution, and reproduction in any mediumnumber of addicts in need of treatment services exceeds
1.2 million [4]. Opiates, mostly opium and crystalline her-
oin (heroin hydrochloride) [5], are the main drugs of abuse
[6-8]. Recent years have seen a substantial shift from
opium use towards using crystalline heroin: some new
official estimates show that as many as 40% of opiate users
consume opium, whereas the remaining users mostly con-
sume different forms of heroin [2].
Generally, more than 80% of drug treatment admissions
in Iran include opiate addicts seeking treatment [2]. Of
various treatment methods, Methadone Maintenance
Treatment (MMT) is considered the treatment of choice.
According to Mokri and Schottenfeld [9], approximately
700 centers offered MMT to addicts in 2007. The treat-
ment success among this group of addicts varies, but a
multi-center study revealed a six-month retention rate of
23%, often requiring repeated treatment episodes [10].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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policy-making requires knowledge of characteristics and
background factors regarding drug addicts. Limited pub-
lished data are available on patients seeking treatment in
addiction treatment centers in Iran. Thus, this study
aimed to investigate patterns of pre-treatment drug
abuse, addiction treatment history, and background
characteristics of patients in MMT attending addiction
treatment centers in Tehran.
Materials and Methods
Subjects
This study was a cross-sectional study of drug users
attending methadone maintenance programs. The target
population comprised all drug users attending metha-
done maintenance programs in addiction treatment cen-
ters in Tehran, Iran, in 2011. Based on the list of MMT
clinics received from the Ministry of Health, more than
95% of the 160 addiction treatment centers in the city
were private clinics. Thus, we focused on the clinics re-
sponsible for the major part of MMT and excluded the
public centers from the study. We used a stratified clus-
ter random sampling technique to cover the three main
socioeconomic regions of the city: North, Center, and
South.
Taking into account the proportion of clinics in each
of the three strata, clinics were randomly selected as
clusters in each study area. Based on the tariffs deter-
mined by the Ministry of Health in Iran, all private ad-
diction treatment centers receive the same monthly fee
from their patients. Thus, variation between the clinics
in terms of the patient costs is minor. The region of the
clinics makes use of the patients’ living area as an indica-
tor of their socioeconomic status. After contacting the
heads of the clinics and introducing the study, we
inquired about their willingness to participate. Among
the first randomly selected eight clinics two did not
agree to participate, thus two substitutes were randomly
selected. Totally, two clinics in the North, and three
clinics in both the Center and South areas participated
in the survey. At these eight centers, patients receiving
MMT were asked to participate. All these patients met
DSM-IV criteria for opioid dependence [11]. Altogether
810 patients participated in the study from January to
May 2011 (response rate = 72%).
Face-to-face interviews
Three trained interviewers conducted structured inter-
views with the participants. Prior to the study, the inter-
viewers received special training and agreed on the
content of the interview, the organization of the clinics,
and how to communicate with the patients. In the clinics,
the interviewers used a standard patient characteristic
form commonly used as a framework in addiction studiesin Iran to conduct structured ten-minute in-person inter-
views. The interviewers requested information on patients’
socioeconomic characteristics (age, gender, years of educa-
tion, marital status, and job status), addiction history prior
to treatment entry: all drugs used for at least one month
in their lives, routes of abuse, the main drug of abuse (the
most problematic drug, which was the main cause for
treatment entry), age when the drug abuse began, the dur-
ation of addiction, and the total amount of money spent
on drugs in the most recent month of abuse. In addition,
the interviewers also inquired about the patients’ MMT
history: their previous methadone treatments, the duration
of current treatment, and the patients’ daily dose of
received methadone.
The interviewers conducted the interviews in collabor-
ation with the clinic nurse, who encouraged the patients
to participate. Patients usually spent some time in the
waiting room before receiving their medication or visit-
ing their doctor, thus providing a good opportunity for
the interview. The interviewer explained the study to the
patients individually and inquired about their willingness
to participate. After the interview, each patient received
a toothbrush and toothpaste as a small gift. The data
collection in each clinic continued to provide the
monthly turnover of patients in the clinic based on the
report provided by the clinic personnel.
Ethical approval
The data collection was carried out using an anonymous
patient characteristic form which aimed to provide as
much confidentiality as possible. The study was volun-
tary, and all respondents provided their written informed
consent. The Tehran University of Medical Sciences Eth-
ics Committee approved the study.
Statistical analysis
The data were transferred from the paper forms to a
digital format. We performed statistical data analysis using
the Statistical Package for the Social Sciences (SPSS for
Windows, version 18), and analyzed any differences in fre-
quencies using the Chi-square test; the t-test served to
compare the means (level of significance< 0.05).
Results
More than 95% of the participants receiving MMT were
men, whereas women comprised 4% of the patients. The
socioeconomic background of the participants appears
in Table 1. The mean age of the patients was 40.5 years
(SD 11.5; range 20–86), a majority (> 60%) of whom
were between 25 and 44 years of age, married (70%), and
employed (> 70%). Over 60% of the female participants
were homemakers. As many as 89% of the patients had
more than elementary school education (65% high
school and 24% university education), whereas the
Table 1 Characteristics and main drug of abuse among
patients receiving MMT (n =810) in Tehran
Variable Male Female Total
N % N % N %
Age
18–24 26 3 4 12 30 4
25–34 263 34 11 33 274 34
35–44 234 30 4 12 238 29
45–54 151 19 10 30 161 20
55–64 81 10 4 12 85 11
65≤ 22 3 − − 22 3
Total 777 33 810
Marital status
Married 541 70 23 70 564 70
Single 164 21 4 12 168 21
Widow 7 1 2 6 9 1
Divorced 64 8 4 12 68 8
Total 776 33 809
Education status
Illiterate 12 2 5 16 17 2
Elementary school 68 9 2 6 70 9
High school 500 66 19 59 519 65
University 183 24 6 19 189 24
Total 763 32 795
Job status (in the last 3 months)
Full time job 424 55 4 13 428 53
Unemployed 115 15 4 13 119 15
Student 10 1 − − 10 1
Retired 74 10 1 3 75 9
Part time job 153 20 3 9 156 19
Homemaker − − 20 63 20 3
Total 776 32 808
Main drug of abuse
Opium 534 69 19 59 553 69
Crystalline Heroin 180 23 11 34 191 24
Other drugs 60 8 2 6 62 8
Total 774 32 806
Table 2 Characteristics of patients receiving MMT
(n =810) in Tehran according to their main drug of abuse
Variable Opium Crystalline Heroin Other Drugs Total
(N %) (N %) (N %) (N %)
Gender
Male 534 (97) 180 (94) 60 (97) 774 (96)
Female 19 (3) 11 (6) 2 (3) 32 (4)
Total 553 191 62 806
Age*
18–24 9 (2) 20 (11) 1 (2) 30 (4)
25–34 140 (25) 100 (52) 32 (52) 272 (34)
35–44 161 (29) 57 (30) 20 (32) 238 (30)
45–54 140 (25) 14 (7) 5 (8) 159 (20)
55–64 81 (15) − 4 (7) 85 (11)
65≤ 22 (4) − − 22 (3)
Total 553 191 62 806
Education status*
Illiterate 14 (3) 3 (2) − 17 (2)
Elementary school 60 (11) 6 (3) 4 (7) 70 (9)
High school 347 (64) 127 (68) 42 (69) 516 (65)
University 121 (22) 52 (28) 15 (25) 188 (24)
Total 542 188 61 791
Job status (in the last 3 months)*
Full time job 305 (55) 93 (49) 28 (45) 426 (53)
Unemployed 64 (12) 36 (19) 19 (31) 119 (15)
Student 4 (1) 6 (3) − 10 (1)
Retired 70 (13) 2 (1) 3 (5) 75(9)
Part time job 97 (18) 47 (25) 11 (18) 155 (19)
Homemaker 12 (2) 6 (3) 1 (2) 19 (2)
Total 552 190 62 804
*Variables with significant differences, p< 0.05.
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were illiterate (2%).
The most commonly reported main drug of abuse
prior to treatment was opium (69%), followed by crystal-
line heroin (24%). Other drugs served as the main drug
of abuse for about 8% of the participants: brown heroin
base (3%), Norjizak (vial heroin) (0.5%) [12], ampheta-
mines (1.2%), methadone (0.6%), cocaine (0.1%), tranqui-
lizers (0.6%), and alcohol (0.1%) among others. In terms
of their lifetime history of drug abuse, more than 90% of
the participants reported using opium, 28% crystalline
heroin, 16% cannabis, 15% amphetamines, and 33%other drugs for at least one month during their addiction
period. Smoking and oral routes were the most prevalent
routes of abuse reported by 79% and 48% of the partici-
pants, respectively. Snorting and injection were reported
as routes of abuse by 5% of the participants. Table 2 pre-
sents the demographic characteristics of the participants
according to the three major drug abuse groups. Crystal-
line heroin abuse was more prevalent in patients under
35 than was opium abuse (p< 0.001; df = 1), and crystal-
line heroin users were more educated than were opium
users (mean 11.6 years vs. 10.6 years; p< 0.05).
A summary of the addiction history of the patients in
the three main drug abuse groups appears in Table 3.
An overwhelming majority of addicts seeking treatment
had used drugs for at least one year, whereas few (3%)
reported a history of addiction to drugs of less than one
year. The mean duration of addiction among the
patients was 10.8 years (SD 7.9). Generally, crystalline
heroin abusers began abusing drugs earlier than did
Table 3 Addiction history of patients receiving MMT









Age of starting drug abuse (years)*
≤ 17 55 (10) 43 (23) 11 (18) 109 (14)
18–24 210 (38) 102 (53) 31 (51) 343 (43)
25–34 187 (34) 43 (23) 14 (23) 244 (31)
35 ≤ 97 (18) 3 (2) 5 (8) 105 (13)
Total (N) 549 191 61 801
Mean (SD) 26.2 (8.6) 21.2 (5.3) 23 (7.8) 24.8 (8.2)
Duration of addiction (years)*
< 1 13 (2) 6 (3) 4 (7) 23 (3)
1–5 144 (26) 61 (33) 18 (30) 223 (28)
6–10 156 (29) 64 (34) 13 (21) 233 (29)
11 ≤ 233 (43) 56 (30) 26 (43) 315 (40)
Total (N) 546 187 61 794
Mean (SD) 11.6 (8.4) 8.7 (6.2) 9.9 (7.8) 10.8 (7.9)
Duration of current treatment (months)*
< 1 67 (12) 21 (11) 5 (8) 93 (12)
1–5.9 144 (26) 61 (32) 12 (20) 217 (27)
6–11.9 126 (23) 47 (25) 4 (7) 177 (22)
12–23.9 112 (20) 32 (17) 10 (16) 154 (19)
24 ≤ 102 (19) 29 (15) 30 (49) 161 (20)
Total (N) 551 190 61 802
Mean (SD) 12.8 (15.6) 10.3 (10.7) 25.2 (25.5) 13.1 (16)
Number of previous MMT admissions*
0 454 (82) 139 (73) 48 (77) 641 (80)
1 ≤ 97 (18) 52 (27) 14 (23) 163 (20)
Total (N) 551 191 62 804
Dosage of methadone (mg)*
≤ 30 mg 193 (36) 41 (22) 16 (26) 250 (32)
35–65 mg 189 (35) 58 (31) 18 (30) 265 (34)
70 mg ≤ 158 (29) 90 (48) 27 (44) 275 (35)
Total (N) 540 189 61 790
Mean (SD) 57.9 (51.6) 70.5 (46) 80.7 (75) 62.6 (52.9)
Drug cost in the last month before treatment entry ($)*
< 50 93 (18) 7 (4) 12 (20) 112 (15)
50–99 133 (25) 6 (3) 7 (12) 146 (19)
100–199 198 (38) 34 (18) 10 (16) 242 (31)
200–499 85 (16) 97 (52) 15 (25) 197 (26)
500 ≤ 17 (3) 43 (23) 17 (28) 77 (10)
Total (N) 526 187 61 774
Mean (SD) 133 (155) 381 (372) 303 (278) 206 (259)
*Variables with significant differences, p< 0.05.
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the starting age for 76% of crystalline heroin abusers was
under 25 years. The duration of addiction among crys-
talline heroin users was shorter than among opium users(mean 8.7 years vs. 11.6 years; p< 0.001). Opium users
reported smoking (77%) and oral route (58%) as the
most common routes of abuse prior treatment. Among
crystalline heroin abusers smoking (94%) was the most
prevalent route of use (Table 4).
For the vast majority (80%) of patients, the treatment
program they were already in was their first MMT epi-
sode (Table 3). The mean duration of current treatment
was 13.1 months (SD 16) and it had lasted at least six
months for most of them (61%). The dose of methadone
participants received ranged from 1.20 mg to 500 mg
(mean 62.6; SD 52.9; median 55.0). The duration of
current treatment was shorter (mean 10.3 months vs.
12.8 months; p< 0.05) and the dosage of methadone was
higher among crystalline heroin users than among
opium users (mean 70.5 mg vs. 57.9 mg; p< 0.05).
About two-thirds of the patients (67%) reported
spending at least USD 100 per month (mean USD 200)
on their drugs during the last month prior to treatment
(Table 3). Crystalline heroin users reported the highest
monthly drug expenses: 75% of them spent at least USD
200 per month on their drugs whereas fewer than 20%
of opium users spent an equivalent amount on theirs.
Discussion
Our study shows that in Tehran, patients receiving
MMT predominantly used opium and crystalline heroin,
whereas other drugs were the main drugs for only a mi-
nority of MMT patients. Generally, the clear majority of
participants receiving MMT were young, educated, mar-
ried, and employed men.
According to the world drug report, in 2009, between
149 and 272 million people between the ages of 15 and
64 consumed illegal drugs, of whom about 10% to 20%
were considered dependent and regular drug users [2].
Patterns of drug dependency vary across countries: Iran,
with more than one million regular drug users, has the
world’s highest rate of dependence on opiate drugs [3,4].
Tehran, as the capital of Iran and with a population
exceeding 12 million, comprises a considerable section
of the population. This study was conducted on MMT
patients of private outpatient treatment centers in
Tehran. Because public centers are so few, our sample
provides a good overview of patients participating in
MMT programs. MMT is the main treatment for opiate
users available at official outpatient medical addiction
treatment centers; consequently, this sample sheds light
on the majority of opiate addiction treatment seekers
who were referred to this official network.
Opium seems still to be the drug of choice among
Iranian addicts given that most studies in Iran acknowl-
edged the higher frequency of addiction to opium than
to other drugs [6,8]. Our results are similar to the find-
ings of a previous study of a group of drug addicts
Table 4 Routes of using drugs prior to treatment among











Yes 425 (77) 180 (94) 29 (48) 634 (79)
No 126 (23) 11 (6) 32 (52) 169 (21)
Total (N) 551 191 61 803
Snorting (Sniffing) route
Yes 4 (1) 14 (7) 10 (16) 28 (4)
No 547 (99) 177 (93) 51 (84) 775 (96)
Total (N) 551 191 61 803
Oral route
Yes 322 (58) 33 (17) 32 (53) 387 (48)
No 229 (42) 158 (83) 29 (47) 416 (52)
Total (N) 551 191 61 803
Injection route
Yes 3(1) 19 (10) 16 (26) 38 (5)
No 548 (99) 172 (90) 45 (74) 765 (95)
Total 551 191 61 803
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reported opium and heroin as the drugs most commonly
abused [7]. The most recent Iranian rapid situation
assessment of drug abuse in 2007 reported opium, crys-
talline heroin, and heroin to be the three most prevalent
drugs previously abused by those attending treatment
centers and in the general population [4]. Similar find-
ings have also been reported in a multi-center study of
seven outpatient centers in four Iranian cities [10]. The
high prevalence of the history of opium use in our study
compared to the estimates in the World Drug Report
2011 might be due to seeking treatment or less stigma-
tized self-report of using opium instead of heroin [2].
Only 1% of the patients reported amphetamines as their
main drug of abuse, but as many as 15% reported using
this drug for at least one month in their lifetime prior to
treatment. Since amphetamines are easily available in
the Iranian drug market in comparison with other sti-
mulants like cocaine [13], and that they may alleviate
some of methadone side effects, they can cause a serious
threat for the treatment process in the MMT clinics in
Iran.
Crystalline heroin users were younger than opium
users, and most of them had begun using drugs at
younger ages. Moreover, the duration of addiction
among crystalline heroin users tended to be shorter than
among opium users. The amount of money most of the
participants had spent on drugs was higher than the
monthly MMT fee in these clinics (i.e. USD 80–90). This
monthly treatment fee consists of a small proportion ofthe average monthly income of an urban family in
Tehran [www.cbi.ir]. Crystalline heroin users had spent
more money on their drugs during their last month of
addiction than had opium addicts. Although a majority
of the participants reported being under some kind of
treatments earlier, most of them were receiving MMT
for the first time. Overall, about 60% of the patients had
been in MMT for more than six months. The mean daily
dose of methadone among crystalline heroin users was
higher than among opium users, but, it was in the
recommended range of 60 to 120 mg [14-16]. Although
the mean daily dose of methadone was in the recom-
mended range, as much as 30% of the patients received
up to 30 mg methadone. In Iran, methadone is usually
prescribed in syrup or tablet forms. In our study the pro-
portion of methadone in syrup and tablet forms among
the MMT patients was about the same.
In line with previous findings, drug abuse is strongly
related to male gender, particularly in the Eastern Medi-
terranean region [17-21]. Little is known about female
addicts in the Middle East, and no comprehensive study
on the prevalence of drug abuse among Iranian women
exists. Consequently, it is unclear whether the low pro-
portion of female participants in our study was due to a
limited number of female addicts in general or their re-
luctance to seek professional help in treatment centers.
Possible reluctance of women to give their consent to
participate in the study was unlikely since the response
rate among female participants (74%) was close to the
overall response rate (72%).
In our study, most of the patients receiving MMT
were fairly young. This is in line with a study by Day
et al. [7] of drug abusers in a general practice in Shiraz,
Iran. Another report of drug abuse among the general
population in Kerman, however, found no significant as-
sociation between drug abuse and age group [8]. Studies
in other countries also show a higher prevalence of ad-
diction among young people [17,18,21,22].
In contrast with other studies of general populations
that reveal lower rates of addiction among more edu-
cated people [6,23], most of the MMT participants in
our study had more than elementary school education.
A study of drug abuse in Thailand reported somewhat
similar findings among addicts in rural areas [21]. As a
review article by Mokri [24] emphasized, most of the
participants attending treatment centers in our study
were also employed. Similar results emerged in another
study of opioid-dependent patients seeking treatment in
a major center in Shiraz [25]. In contrast, another study
of opium use in a rural area of Iran found a significant
association between opium use and unemployment [6].
On the other hand, in a population-based study of
opium use in Fars province, opium use cut across all
employment status groups [23]. The differences between
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studies in similar settings with general population of
addicts reflect the diversity of the patients in terms of
their socioeconomic status including education and em-
ployment. This indicates that in-treatment patients may
be of higher socioeconomic level and may have more
resources than the other addicts.
Bearing in mind that this study was a cross-sectional
survey of patients attending outpatient addiction treat-
ment centers, no causal inferences of underlying factors
can be outlined. In addition, the findings from patients
in MMT cannot be generalized to the whole population
of drug users. One limitation of the study is that because
of practical reasons only eight clinics were included in
the study. Although the data are based on patients’ self-
reported addiction history, we tried to decrease the like-
lihood of underreporting via good collaboration with the
clinic staff. However, it has to be kept in mind that ten-
dency towards “social desirability” among clients in a
good therapeutic alliance to caregivers can be a source
of under-reporting. This limitation is true for all studies
regarding drug abuse history.
Despite these limitations, our study has several
strengths. The stratified random sampling method out-
lined well patients seeking treatment in addiction treat-
ment centers from all three main socioeconomic areas
of the city. In addition to the broad coverage, the large
sample size along with the high response rate in this
marginalized target group bolsters the reliability of the
results in this capital city of more than 12 million. It is
worth mentioning that our response rate of 72% may be
somewhat low, as it is based on the number of study
participants among the total monthly turnover in the
clinics, rather than on the number of patients asked to
participate. Furthermore, by utilizing a structured inter-
view instead of a self-administered questionnaire, we
reduced the possibility of misunderstandings in this
compromised group.
Our study provides valuable information about the
characteristics of patients attending addiction treatment
centers in Iran. Although Tehran represents a consider-
able proportion of the Iranian population, a national sur-
vey of all drug abusers would be necessary to obtain a
more thorough understanding of the predisposing fac-
tors associated with illegal drug abuse.
Conclusion
The present study has demonstrated that among Iranian
former drug addicts attending addiction treatment cen-
ters, opium and crystalline heroin are the drugs of
choice. The growing number of addicts utilizing more
dangerous drugs such as crystalline heroin calls for more
educational and preventive strategies targeting younger
age groups in particular.Abbreviations
MMT: Methadone Maintenance Treatment.
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